share_log

BioVie | 8-K: Current report

BioVie | 8-K: Current report

BioVie | 8-K：重大事件
美股SEC公告 ·  10/29 06:05

Moomoo AI 已提取核心信息

On October 28, 2024, BioVie Inc., a clinical-stage company focused on developing treatments for chronic debilitating conditions, announced a registered direct offering of 1,146,000 shares of its common stock at a price of $2.83 per share. The offering, which is expected to close on October 29, 2024, is anticipated to generate gross proceeds of approximately $3.2 million before deducting fees and expenses. BioVie has entered into an agreement with ThinkEquity LLC, who will act as the placement agent. In addition to the share offering, BioVie issued a warrant to ThinkEquity, allowing the purchase of additional shares at a future date. The company plans to use the net proceeds for working capital and general corporate purposes. The shares and warrants were offered under a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission. The offering is subject to customary closing conditions, and the company has made forward-looking statements regarding the expected completion of the offering.
On October 28, 2024, BioVie Inc., a clinical-stage company focused on developing treatments for chronic debilitating conditions, announced a registered direct offering of 1,146,000 shares of its common stock at a price of $2.83 per share. The offering, which is expected to close on October 29, 2024, is anticipated to generate gross proceeds of approximately $3.2 million before deducting fees and expenses. BioVie has entered into an agreement with ThinkEquity LLC, who will act as the placement agent. In addition to the share offering, BioVie issued a warrant to ThinkEquity, allowing the purchase of additional shares at a future date. The company plans to use the net proceeds for working capital and general corporate purposes. The shares and warrants were offered under a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission. The offering is subject to customary closing conditions, and the company has made forward-looking statements regarding the expected completion of the offering.
2024年10月28日，biovie公司，一家专注于研发治疗慢性致残疾病的临床阶段公司，宣布以每股2.83美元的价格注册直接发行114.6万股普通股。预计将于2024年10月29日结束的发行预计将在扣除费用和支出前产生约320万美元的总收益。BioVie已与ThinkEquity LLC达成协议，后者将担任配售代理。除了股票发行外，BioVie还向ThinkEquity发行了一项认股权证，允许其在将来某个日期购买额外股票。公司计划将净收益用于营运资金和一般企业用途。这些股票和认股权证是根据此前提交并获得美国证券交易委员会批准的注册声明书中提供的。该发行受惯例的 closing conditions 条款约束，并且公司已就发行的预期完工发表前瞻性声明。
2024年10月28日，biovie公司，一家专注于研发治疗慢性致残疾病的临床阶段公司，宣布以每股2.83美元的价格注册直接发行114.6万股普通股。预计将于2024年10月29日结束的发行预计将在扣除费用和支出前产生约320万美元的总收益。BioVie已与ThinkEquity LLC达成协议，后者将担任配售代理。除了股票发行外，BioVie还向ThinkEquity发行了一项认股权证，允许其在将来某个日期购买额外股票。公司计划将净收益用于营运资金和一般企业用途。这些股票和认股权证是根据此前提交并获得美国证券交易委员会批准的注册声明书中提供的。该发行受惯例的 closing conditions 条款约束，并且公司已就发行的预期完工发表前瞻性声明。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间